Enhancing Site Selection and Feasibility Using KRIs

Introduction: Why Site Selection Matters in RBM

One of the most pivotal decisions in any clinical trial is choosing the right investigational sites. A poor-performing site can lead to protocol deviations, data quality issues, delays in subject enrollment, and regulatory risks. Traditionally, site selection has been based on investigator reputation, self-reported metrics, and past relationships. However, Risk-Based Monitoring (RBM) introduces a data-driven layer to this process—Key Risk Indicators (KRIs).

KRIs bring objectivity by assessing historical performance across metrics like data entry lag, deviation frequency, protocol compliance, and query resolution rates. Leveraging KRIs during feasibility and site selection helps sponsors identify low-risk sites that align with trial complexity. As per ICH E6(R2) and FDA’s RBM guidance, integrating KRIs into feasibility ensures risk-proportionate oversight from the very beginning.

What KRIs Are Relevant for Site Selection?

During the feasibility phase, sponsors and CROs can evaluate a site’s past and predicted performance using the following KRIs:

• Data Entry Timeliness: Average delay in entering CRF data
• Query Resolution Rate: % of queries resolved within 7–14 days
• Protocol Deviation Rate: Per subject or per enrolled patient
• Audit/Inspection Findings: Frequency and severity of GCP issues
• Enrollment Forecast Accuracy: Difference between projected and actual recruitment
• Informed Consent Error Rate: History of ICF documentation issues

These KRIs are extracted from previous trials through CTMS, eTMF, or clinical data repositories. In adaptive trials or complex oncology studies, these indicators are especially critical.

Building a KRI-Based Site Scorecard

To streamline decision-making, sponsors often build a site feasibility scorecard integrating KRI data. An example is shown below:

This scorecard helps prioritize site qualification visits, additional feasibility questions, or exclusion if risk exceeds a threshold. For feasibility SOP templates, visit PharmaSOP.

Incorporating KRIs into Site Feasibility Questionnaires

To formalize the KRI evaluation, feasibility questionnaires can be expanded to ask site teams about their historical metrics. Sample additions include:

• Average time to complete eCRFs in past 3 studies
• Number of critical audit findings in past 2 years
• Deviation rate per trial phase
• Success rate in meeting enrollment targets

Responses can be validated using CTMS or sponsor-maintained dashboards. This shifts feasibility from subjective estimation to evidence-based selection.

Using KRIs to Match Protocol Complexity with Site Capability

Not every site is suited for every protocol. Complex protocols with adaptive randomization, narrow visit windows, or intensive data collection demand high-performing sites. Using KRIs, sponsors can match:

• Complex PK Sampling Trials: Require sites with low data lag and zero critical deviations
• Pediatric Trials: Need sites with ICF compliance history and trained staff
• Decentralized Trials: Favor sites with remote data handling capabilities and fast query closure

This matching reduces downstream protocol violations and improves patient safety. It also minimizes the need for corrective actions mid-study.

Regulatory Benefits and Risk Mitigation

Regulatory authorities increasingly expect that site selection is part of risk assessment. EMA’s Reflection Paper and ICH E6(R2) both encourage structured feasibility and site qualification based on past performance.

During inspections, regulators may ask for documentation of:

• Site evaluation criteria
• Performance benchmarks
• Reasons for site exclusion
• Action plans for high-risk sites that were included

Using KRIs as documented criteria demonstrates proactive quality risk management aligned with GCP expectations. Visit PharmaValidation to explore validation workflows for site feasibility tools.

Best Practices for Using KRIs in Feasibility

• Maintain a central repository of site-level KRIs across previous trials
• Involve CRA, QA, and Medical Monitors in scoring methodology
• Use predictive models to correlate KRI history with trial performance
• Balance KRI metrics with therapeutic area expertise and patient access
• Revalidate KRI thresholds periodically across therapeutic portfolios

Effective site selection is both an operational and scientific decision. KRIs provide the missing link to forecast site success accurately.

Conclusion

Integrating KRIs into site selection and feasibility ensures a proactive, data-driven approach to clinical trial success. It minimizes avoidable risks, aligns with regulatory expectations, and streamlines monitoring efforts downstream. In the RBM era, feasibility without KRIs is an incomplete strategy.

Further Reading

• FDA Risk-Based Monitoring Guidance
• EMA Reflection Paper on Risk-Based Quality Management
• ICH E6(R2) Guideline